Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas

Molecular Oncology

Volumn 1, Issue 4, 2008, Pages 425-430

  Kannengiesser, Caroline ^a   Spatz, Alain ^a   Michiels, Stefan ^a   Eychène, Alain ^b   Dessen, Philippe ^a   Lazar, Vladimir ^a   Winnepenninckx, Véronique ^c   Lesueur, Fabienne ^a   Druillennec, Sabine ^b   Robert, Caroline ^a   van den Oord, Joost J ^c   Sarasin, Alain ^a   Bressac de Paillerets, Brigitte ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CNRS   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

BRAF; Genomics; Melanoma

Indexed keywords

B RAF KINASE; CD63 ANTIGEN; HEAT SHOCK PROTEIN 70; MELANOMA ANTIGEN 2; MITOGEN ACTIVATED PROTEIN KINASE; OLIGONUCLEOTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER GROWTH; CANCER IMMUNOLOGY; CELL MOTILITY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE PROBE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMOBILIZED CELL; IMMUNITY; IMMUNOGENICITY; IN VITRO SELECTION; MALE; MELANOMA; MELANOSOME; MICROARRAY ANALYSIS; NRAS GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROBABILITY; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL MOVEMENT; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DNA PROBES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNITY; INFANT; MALE; MELANOMA; MELANOSOMES; MIDDLE AGED; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 40849119670     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.01.002     Document Type: Article

References (35)

1. Bloethner S., Hemminki K., Thirumaran R.K., Chen B., Mueller-Berghaus J., Ugurel S., Schadendorf D., and Kumar R. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. Melanoma Res. 16 (2006) 297-307
2. Buchholz M., Biebl A., Neesse A., Wagner M., Iwamura T., Leder G., Adler G., and Gress T.M. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 63 (2003) 4945-4951
3. Cao M.G., Auge J.M., Molina R., Marti R., Carrera C., Castel T., Vilella R., Conill C., Sanchez M., Malvehy J., and Puig S. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res. 27 (2007) 595-599
4. Chang D.Z., Panageas K.S., Osman I., Polsky D., Busam K., and Chapman P.B. Clinical significance of BRAF mutations in metastatic melanoma. J. Transl. Med. 2 (2004) 46
5. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
6. Dong J., Phelps R.G., Qiao R., Yao S., Benard O., Ronai Z., and Aaronson S.A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63 (2003) 3883-3885
7. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., and Marais R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66 (2006) 9483-9491
8. Elsner L., Muppala V., Gehrmann M., Lozano J., Malzahn D., Bickeboller H., Brunner E., Zientkowska M., Herrmann T., Walter L., Alves F., Multhoff G., and Dressel R. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J. Immunol. 179 (2007) 5523-5533
9. Gesierich S., Paret C., Hildebrand D., Weitz J., Zgraggen K., Schmitz-Winnenthal F.H., Horejsi V., Yoshie O., Herlyn D., Ashman L.K., and Zoller M. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin. Cancer Res. 11 (2005) 2840-2852
10. Giordano T.J., Kuick R., Thomas D.G., Misek D.E., Vinco M., Sanders D., Zhu Z., Ciampi R., Roh M., Shedden K., Gauger P., Doherty G., Thompson N.W., Hanash S., Koenig R.J., and Nikiforov Y.E. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 (2005) 6646-6656
11. Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., and Dummer R. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19 (2006) 290-302
12. Iida J., Skubitz A.P., McCarthy J.B., and Skubitz K.M. Protein kinase activity is associated with CD63 in melanoma cells. J. Transl. Med. 3 (2005) 42
13. Jackson S., Harland M., Turner F., Taylor C., Chambers P.A., Randerson-Moor J., Swerdlow A.J., dos Santos Silva I., Beswick S., Bishop D.T., and Newton Bishop J.A. No evidence for BRAF as a melanoma/nevus susceptibility gene. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 913-918
14. Johansson P., Pavey S., and Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res. 20 (2007) 216-221
15. Kidd M., Modlin I.M., Mane S.M., Camp R.L., Eick G., and Latich I. The role of genetic markers-NAP1L1, MAGE-D2, and MTA1-in defining small-intestinal carcinoid neoplasia. Ann. Surg. Oncol. 13 (2006) 253-262
16. Kim I.J., Kang H.C., Jang S.G., Ahn S.A., Yoon H.J., and Park J.G. Development and applications of a BRAF oligonucleotide microarray. J. Mol. Diagn. 9 (2007) 55-63
17. Korn E.L., Li M.C., McShane L.M., and Simon R. An investigation of two multivariate permutation methods for controlling the false discovery proportion. Stat. Med. 26 (2007) 4428-4440
18. Kumar R., Angelini S., Czene K., Sauroja I., Hahka-Kemppinen M., Pyrhonen S., and Hemminki K. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 9 (2003) 3362-3368
19. Kumar R., Angelini S., Snellman E., and Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 122 (2004) 342-348
20. Lang J., Boxer M., and MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat. 21 (2003) 327-330
21. Latysheva N., Muratov G., Rajesh S., Padgett M., Hotchin N.A., Overduin M., and Berditchevski F. Syntenin-1 is a new component of tetraspanin-enriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. Mol. Cell. Biol. 26 (2006) 7707-7718
22. Laud K., Kannengiesser C., Avril M.F., Chompret A., Stoppa-Lyonnet D., Desjardins L., Eychene A., Demenais F., Lenoir G.M., and Bressac-de Paillerets B. BRAF as a melanoma susceptibility candidate gene?. Cancer Res. 63 (2003) 3061-3065
23. Lazo P.A. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 98 (2007) 1666-1677
24. Le Naour F., Andre M., Greco C., Billard M., Sordat B., Emile J.F., Lanza F., Boucheix C., and Rubinstein E. Profiling of the tetraspanin web of human colon cancer cells. Mol. Cell. Proteomics. 5 (2006) 845-857
25. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., and Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
26. Michaloglou C., Vredeveld L.C., Mooi W.J., and Peeper D.S. BRAF(E600) in benign and malignant human tumours. Oncogene (2007) 2007 [Epub ahead of print]
27. Omholt K., Platz A., Kanter L., Ringborg U., and Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9 (2003) 6483-6488
28. Papageorgio C., Brachmann R., Zeng J., Culverhouse R., Zhang W., and McLeod H. MAGED2: a novel p53-dissociator. Int. J. Oncol. 31 (2007) 1205-1211
29. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N.K., Trent J.M., and Meltzer P.S. High frequency of BRAF mutations in nevi. Nat. Genet. 33 (2003) 19-20
30. Patton E.E., Widlund H.R., Kutok J.L., Kopani K.R., Amatruda J.F., Murphey R.D., Berghmans S., Mayhall E.A., Traver D., Fletcher C.D., Aster J.C., Granter S.R., Look A.T., Lee C., Fisher D.E., and Zon L.I. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15 (2005) 249-254
31. Pavey S., Johansson P., Packer L., Taylor J., Stark M., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A., O'Rourke M.G., Parsons P.G., Meltzer P., Ringner M., and Hayward N.K. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23 (2004) 4060-4067
32. Rothhammer T., and Bosserhoff A.K. Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma. Melanoma Res. 16 (2006) 309-316
33. Shinozaki M., Fujimoto A., Morton D.L., and Hoon D.S. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 10 (2004) 1753-1757
34. Smalley K.S., and Herlyn M. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. J. Invest. Dermatol. 123 (2004) xvi-xvii
35. Winnepenninckx V., Lazar V., Michiels S., Dessen P., Stas M., Alonso S.R., Avril M.F., Ortiz Romero P.L., Robert T., Balacescu O., Eggermont A.M., Lenoir G., Sarasin A., Tursz T., van den Oord J.J., and Spatz A. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl. Cancer Inst. 98 (2006) 472-482